Eli Lilly (NY:LLY)

1,143.12 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Via MarketBeat

Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? ↗

September 23, 2026

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Via MarketBeat

Topics Intellectual Property Lawsuit

Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗

September 23, 2026

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Via The Motley Fool

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗

September 22, 2026

IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.

Via The Motley Fool

Topics ETFs

Eli Lilly (NYSE:LLY) Fits a Dividend Quality Screen Despite Its Low Yield ↗

September 18, 2026

Via Chartmill

Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems ↗

September 22, 2026

Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?

Via The Motley Fool

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? ↗

September 22, 2026

VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.

Via The Motley Fool

Topics ETFs

Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring ↗

September 22, 2026

Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.

Via MarketBeat

Topics Initial Public Offering

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? ↗

September 22, 2026

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Via The Motley Fool

Topics Economy

Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. ↗

September 22, 2026

Viking and Roche both reported positive results for their weight-loss drugs Tuesday.

Via Investor's Business Daily

2 Cash-Producing Stocks with Exciting Potential and 1 We Brush Off

September 22, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem

September 21, 2026

Via AB Newswire

Topics Animal Testing

Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016 ↗

September 21, 2026

The top healthcare stock has been underperforming the market, and its returns haven't been as impressive as in recent years.

Via The Motley Fool

Meet the Vanguard ETF That Increased Its SpaceX Holding by 39% in 1 Month and Shows No Signs of Slowing Down ↗

September 20, 2026

The unlocking of SpaceX shares is reshaping the communications sector.

Via The Motley Fool

Topics ETFs

Why Twist Bioscience Stock Skyrocketed This Week ↗

September 18, 2026

It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.

Via The Motley Fool

Topics Artificial Intelligence

Better Buy for Cautious Investors: Eli Lilly vs Costco ↗

September 18, 2026

These companies may perform well in any market environment.

Via The Motley Fool

Topics Artificial Intelligence Economy

Automated Labeling Tools Are Modernizing the AI Training Dataset Market ↗

September 18, 2026

The global AI training dataset market was valued at USD 3.2 billion in 2025 and is projected to reach USD 16.3 billion by 2033, expanding from USD 3.9 bill

Via Talk Markets

Topics Artificial Intelligence

1 Safe-and-Steady Stock Worth Your Attention and 2 We Question

September 18, 2026

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Ch...

Via StockStory

Topics Emissions

Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗

September 17, 2026

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Via The Motley Fool

This Trend is Excellent News for Eli Lilly and Its Investors ↗

September 17, 2026

Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.

Via The Motley Fool

Does Fidelity or iShares Have the Better Healthcare ETF For Investors Seeking Broad Exposure? ↗

September 16, 2026

FHLC delivered 24% returns over one year with a 0.08% expense ratio, while IXJ offers global diversification but trails on performance and costs more to own.

Via The Motley Fool

Topics ETFs

5 Buy-and-Hold Stocks Built to Weather a Volatile Market ↗

September 16, 2026

Ahead of Q4 2026, analysts favor Western Digital, NVIDIA, Vertiv, Eli Lilly, and JPMorgan Chase as steady, best-in-class stocks offering growth with less volatility for buy-and-hold investors.

Via MarketBeat

Topics Artificial Intelligence

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗

September 16, 2026

The company is still looking to bounce back after the beating it took in recent years.

Via The Motley Fool

Topics Economy

VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗

September 15, 2026

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

Via The Motley Fool

Topics ETFs

Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything ↗

September 15, 2026

The drugmaker has a lot riding on continued clinical progress.

Via The Motley Fool

3 Healthcare Stocks for 3 Stages of Life ↗

September 15, 2026

Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.

Via MarketBeat

3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 ↗

September 15, 2026

These stocks have been struggling lately, but they could be underrated buys in the long run.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets ↗

September 14, 2026

Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing...

Via MarketBeat

This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy? ↗

September 14, 2026

The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those.

Via The Motley Fool

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗

September 14, 2026

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.